Found: 33
Select item for more details and to access through your institution.
The impact of red blood cell transfusion practices on inpatient mortality in variceal and non‐variceal gastrointestinal bleeding patients: a 20‐year US nationwide retrospective analysis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 41, doi. 10.1111/apt.16965
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 1, doi. 10.1111/apt.16411
- Publication type:
- Article
Editorial: acute severe autoimmune hepatitis—a diagnostic and therapeutic dilemma.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Editorial: seeing the light at the end of gastroscope ‐ complications after elective procedures are ready for NICE, bright decision aid tools ‐ authors' reply.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Editorial: chronic DILI and HILI—corticosteroid plus glycyrrhizin as standard therapy? Authors' reply.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Letter: non‐selective beta‐blockers in cirrhosis—effect beyond portal hypertension. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 186, doi. 10.1111/apt.16982
- By:
- Publication type:
- Article
Letter: normalizing the ileoanal pouch—more than a one‐step technique. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 176, doi. 10.1111/apt.16988
- By:
- Publication type:
- Article
Letter: the effect of anti‐COVID‐19 treatment on the outcome of patients with inflammatory bowel disease—authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 179, doi. 10.1111/apt.16978
- By:
- Publication type:
- Article
Editorial: group‐based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome—authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 160, doi. 10.1111/apt.16985
- By:
- Publication type:
- Article
Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID‐19 pandemic—authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 178, doi. 10.1111/apt.16977
- By:
- Publication type:
- Article
Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 182, doi. 10.1111/apt.16972
- By:
- Publication type:
- Article
Review article: current and emerging therapies for acute alcohol‐associated hepatitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 28, doi. 10.1111/apt.16969
- By:
- Publication type:
- Article
AP&T: Editorsʼ declarations of interest.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 4, doi. 10.1111/apt.16967
- Publication type:
- Article
Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 131, doi. 10.1111/apt.16926
- By:
- Publication type:
- Article
Editorial: COVID‐19 vaccines are safe and effective in patients with inflammatory bowel disease—but many unanswered questions remain. Authors' reply.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Editorial: seeing the light at the end of gastroscope—Complications after elective procedures are ready for NICE, bright decision aid tools.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 6, doi. 10.1111/apt.16952
- By:
- Publication type:
- Article
Editorial: group‐based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
The risk of unexpected hospital admissions and primary care visits after an elective day‐case gastroscopy: a cohort study within England.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 56, doi. 10.1111/apt.16946
- By:
- Publication type:
- Article
Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD – not everyone fits the mould.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 180, doi. 10.1111/apt.16931
- By:
- Publication type:
- Article
Letter: normalising the ileoanal pouch—more than a one‐step technique.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 174, doi. 10.1111/apt.16954
- By:
- Publication type:
- Article
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a "real world" study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 144, doi. 10.1111/apt.16945
- By:
- Publication type:
- Article
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 95, doi. 10.1111/apt.16923
- By:
- Publication type:
- Article
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: a self‐controlled case series study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 121, doi. 10.1111/apt.16894
- By:
- Publication type:
- Article
Editorial: chronic DILI and HILI – corticosteroid plus glycyrrhizin as standard therapy?
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Editorial: timing of carvedilol – promoting survivors in cirrhosis.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 110, doi. 10.1111/apt.16939
- By:
- Publication type:
- Article
Letter: non‐selective beta‐blockers in cirrhosis‐effect beyond portal hypertension.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 184, doi. 10.1111/apt.16941
- By:
- Publication type:
- Article
Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 84, doi. 10.1111/apt.16892
- By:
- Publication type:
- Article
Editorial: COVID‐19 vaccines are safe and effective in patients with inflammatory bowel disease—but many unanswered questions remain.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 67, doi. 10.1111/apt.16867
- By:
- Publication type:
- Article
Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within 14‐day treatment cycle in Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 77, doi. 10.1111/apt.16852
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 1, p. 1, doi. 10.1111/apt.16411
- Publication type:
- Article